|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
injection
|
|
gptkbp:age
|
4 years and older
|
|
gptkbp:alsoKnownAs
|
Dengue Tetravalent Vaccine (Live, Attenuated)
QDENGA
|
|
gptkbp:approvalYear
|
2022
|
|
gptkbp:approvedBy
|
gptkb:Argentina
gptkb:Brazil
gptkb:European_Union
gptkb:Iceland
gptkb:Indonesia
gptkb:Liechtenstein
gptkb:Malaysia
gptkb:Norway
gptkb:Singapore
gptkb:Thailand
gptkb:UK
|
|
gptkbp:clinicalTrialPhase
|
gptkb:TIDES
Phase 3
|
|
gptkbp:composition
|
live attenuated dengue virus strains
|
|
gptkbp:containsSerotype
|
gptkb:DENV-1
gptkb:DENV-2
gptkb:DENV-3
gptkb:DENV-4
|
|
gptkbp:developedBy
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:dosingSchedule
|
two doses, three months apart
|
|
gptkbp:effect
|
approximately 80% against symptomatic dengue (first 12 months after vaccination)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
TAK-003
|
|
gptkbp:indication
|
prevention of dengue fever
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:target
|
gptkb:dengue
|
|
gptkbp:type
|
live attenuated vaccine
|
|
gptkbp:WHOStatus
|
prequalified (2024)
|
|
gptkbp:bfsParent
|
gptkb:Qdenga
|
|
gptkbp:bfsLayer
|
6
|